Strategic Thrusts Banner
Engineering CELLS,
   Engineering RESPONSES
14
Jul 2015

Agilent Technologies and A*STAR’s Bioprocessing Technology Institute Collaborate on New Bioanalytical Methodologies

Agilent Technologies Inc. and the Bioprocessing Technology Institute (BTI), a research institute of Singapore’s Agency for Science, Technology and Research (A*STAR) today announced that they will collaborate on new analytical approaches to analyzing specific protein-linked sugar compounds.

26
Sep 2014

Protecting the body from itself

Scientists from A*STAR’s Bioprocessing Technology Institute (BTI) have established a clearer relationship between two cells which serve our body’s natural defence mechanisms against diseases and infections. Their findings, published in the prestigious journal CELL REPORTS, will help the medical community better understand autoimmunity and could pave the way for treatment of autoimmune diseases.

01
Sep 2014

Understanding and improving the body's fight against pathogens

Scientists from A*STAR’s Bioprocessing Technology Institute (BTI) have uncovered the crucial role of two signalling molecules, DOK3 and SHP1, in the development and production of plasma cells. These discoveries, published in two prestigious journals PNAS and Nature Communications, advance the understanding of plasma cells and the antibody response, and may lead to optimisation of vaccine development and improved treatment for patients with autoimmune diseases such as lupus and tumours such as multiple myeloma.

14
Jul 2014

A*STAR partners Roche to develop new cancer therapeutics

A*STAR’s Bioprocessing Technology Institute (BTI) has entered into an agreement with one of the world’s largest pharmaceutical company, Roche, to identify novel drug candidates for the detection and treatment of cancer. The partnership brings together BTI’s capabilities in novel antibody discovery and Roche’s expertise in developing monoclonal antibody (mAbs) therapeutics, opening up the possibility of improved treatment for cancer, a leading cause of death worldwide.

12
Feb 2014

A*STAR's Bioprocessing Technology Institute (BTI) partners South Korean Institutes to advance glycomics research in Asia

A*STAR’s Bioprocessing Technology Institute (BTI) today signed Memorandums of Understanding (MoUs) with Korea Basic Science Institute (KBSI) and Chungnam National University’s Graduate School of Analytics Science and Technology (GRAST) to advance collaboration between Singapore and South Korea in the field of glycomics in Asia. The agreements were signed by the three organisations at the first Singapore-South Korea Symposium on Glycomics (SKSG), held from 12 – 13 February 2014.

23
May 2013

Agilent Technologies, University of Rouen and A*STAR’S Bioprocessing Technology Institute to Further Innovation in Biopharmaceuticals and Glycomics

Agilent Technologies Inc. (NYSE: A), the Glyco-MEV laboratory at the University of Rouen, in France, and the Bioprocessing Technology Institute at the Agency for Science, Technology and Research (A*STAR) in Singapore, have signed a memorandum of understanding to work together to develop tools to effectively analyze biologics and vaccines.

19
Mar 2013

A*STAR’S Antibody Technology Bags Regional Award

VeriStem Technologies, a spin-off from A*STAR’s Bioprocessing Technology Institute (BTI), has been awarded the Biospectrum Asia-Pacific Emerging Companies of the Year Award 2013. Shortlisted from start-up companies spanning the biotechnology, medical technology, and pharmaceutical sectors across the Asia-Pacific region, winners are chosen for developing innovative technology that has the potential to bring out revolutionary changes in the healthcare industry. As one of this year’s recipients, VeriStem Technologies has won the award for its highly-effective tools that enable the development and manufacture of safe stem cell therapies.

13
Dec 2012

Singapore Scientists Identify New Biomarker for Cancer in Bone Marrow

Singapore scientists have identified FAIM, a molecule that typically prevents cell death, as a potential biomarker to identify an incurable form of cancer in the bone marrow. Patients with this form of cancer usually do not get cured with current standard treatments such as chemotherapy and stem cell transplantation, with an average survival of only about four years. FAIM could thus be a therapeutic target in these patients, as drugs developed to target the molecule could destroy multiple myeloma cells and hence eradicate the cancer.

11
May 2012

A*STAR Scientists Discover ‘Switch’ To Boost Anti-Viral Response To Fight Infectious Diseases

Singapore scientists from Bioprocessing Technology Institute (BTI) under the Agency of Science, Technology and Research (A*STAR) have for the first time, identified the molecular ‘switch’ that directly triggers the body’s first line of defence against pathogens, more accurately known as the body’s “innate immunity”. The scientists found that this ‘switch’ called Bruton’s tyrosine kinase (BTK) when turned on, activates the production of interferons - a potent class of virus killers that enables the body to fight harmful pathogens such as dengue and influenza viruses.

28
Nov 2011

Singapore scientists lead human embryonic stem cell study to advance the field of regenerative medicine research

Researchers from A*STAR Singapore took lead roles in a study that identified a portion of the genome mutated during long-term culture of human embryonic stem cells (hESCs). The study was a worldwide collaboration, led by Drs Peter Andrews of the University of Sheffield (UK), Paul Robson of the Genome Institute of Singapore (GIS), Steve Oh of Singapore’s Bioprocessing Technology Institute (BTI), and Barbara Knowles and others in the international stem cell community. The GIS, IMB and BTI are research institutes under the umbrella of the Agency for Science, Technology and Research, (A*STAR), Singapore.